AbbVie's next-generation toxin candidate gains approval in Canada; U.S. pathway remains unclear.
Allergan Aesthetics has secured Health Canada approval for Boey, a rapid-onset, short-duration neuromodulator indicated for glabellar lines. The approval represents a significant step forward for AbbVie's next-generation toxin platform, though U.S. FDA status remains unconfirmed.
Boey is engineered to onset faster than Botox (typically 3–5 days versus 7–14 days) while maintaining a shorter duration of effect—a profile designed to appeal to patients seeking flexibility and practitioners seeking faster patient satisfaction. The mechanism involves a proprietary formulation and delivery system distinct from traditional botulinum toxin A preparations. Health Canada's approval validates the safety and efficacy profile and signals likely FDA submission in the near term.
Rapid-onset neuromodulator with shorter duration—designed for patient flexibility.
For U.S. practices, Boey represents potential disruption to the neuromodulator market if approved. Faster onset could drive patient preference and higher treatment frequency, while shorter duration may reduce per-patient lifetime value. AbbVie's dominance in the toxin market means this launch will be heavily promoted through Allē and bundled rebate structures.
Source: original report ↗
Frequently asked questions
How fast does Boey work compared to Botox?
Boey typically onsets in 3–5 days, compared to Botox's standard 7–14 days. This faster onset is one of Boey's key differentiators and is designed to improve patient satisfaction by delivering visible results more quickly.
Is Boey approved in the United States?
Boey has received Health Canada approval but U.S. FDA status remains unconfirmed. AbbVie is expected to submit to the FDA in the near term, but no approval timeline has been announced.
What is the duration of Boey compared to traditional neuromodulators?
Boey is engineered to have a shorter duration of effect than Botox, though the exact duration window has not been specified in the approval. This shorter profile is intended to appeal to patients seeking more flexibility in treatment frequency.
What indication did Health Canada approve Boey for?
Boey is indicated for glabellar lines (frown lines between the eyebrows). This is the same primary indication as Botox and other established neuromodulators.
How will Boey affect my practice's neuromodulator revenue?
Faster onset and shorter duration could increase treatment frequency and patient preference, but may reduce per-patient lifetime value per treatment cycle. AbbVie will likely promote Boey through Allē rewards and bundled rebate structures, which could shift patient demand away from competitors.
What makes Boey different from Botox at the formulation level?
Boey uses a proprietary formulation and delivery system distinct from traditional botulinum toxin A preparations, which enables its faster onset profile. The exact technical differences have not been publicly detailed beyond this description.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
